Previous Article | Next Article ![]()
Journal of Clinical Microbiology, August 2002, p. 2828-2831, Vol. 40, No. 8
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.8.2828-2831.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais,1 Núcleo de Estudos de Doenças Infecciosas e Tropicais, TRÓPICA, Faculdade de Ciências Médicas, Universidade Federal de Mato Grosso, Cuiaba, Mato Grosso, Brazil2
Received 24 July 2001/ Returned for modification 24 December 2001/ Accepted 8 May 2002
In vitro, terbinafine is highly active against a broad spectrum of pathogenic fungi. We evaluated the activities of terbinafine and itraconazole against 31 isolates of Paracoccidioides brasiliensis. The tests were conducted by using a broth macrodilution procedure. MICs, in micrograms per milliliter, were as follows: terbinafine, 0.015 to 1.0 (geometric mean, 0.1188); itraconazole, 0.007 to 0.5 (geometric mean, 0.03165). The usual therapy for paracoccidioidomycosis is sulfonamides, amphotericin B, and azole derivatives (ketoconazole, itraconazole, and fluconazole). In comparison to amphotericin B, azole derivatives allow shorter treatment courses, can be administered orally, and are equally effective. Itraconazole has as high efficacy as ketoconazole, but with superior tolerance. It is the current drug of choice for treatment of paracoccidioidomycosis. The data obtained in this study indicate that terbinafine is active against P. brasiliensis in vitro and suggest that this allylamine can be considered a new option as drug therapy for paracoccidioidomycosis.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|